Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: Correlation with p53, MIB-1, and outcome
Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: Correlation with p53, MIB-1, and outcome
复制标题
DOI：
10.1097/01.pgp.0000235064.93182.ec
复制
发表时间：
2007-04-01
影响因子：
2.4
通讯作者：
Brustmann, Hermann
中科院分区：
文献类型：
--
作者：
Brustmann, Hermann
本研究通过免疫组化方法研究了多聚腺苷二磷酸核糖聚合酶（PARP）在卵巢浆液性癌中的表达与预后、临床病理参数、MIB-1标记指数（LIs）评估的增殖和p53免疫表达的关系。用PARP、MIB-1和p53抗体对50例卵巢浆液性癌福尔马林固定、石蜡包埋的存档组织进行免疫染色。此外，10例良性浆液性囊腺瘤和10例典型浆液性交界性卵巢肿瘤也被纳入PARP免疫研究。根据阳性染色细胞核的数量和强度，将PARP免疫染色评分为阴性、低或强。将MIB-1U定量为1000个细胞核中阳性染色细胞核的百分比。对于p53，至少10%的肿瘤细胞必须显示核染色。PARP在所有浆液性囊腺瘤中的表达均为阴性，在浆液性交界性卵巢肿瘤中的表达较低。38例（76%）卵巢浆液性癌PARP强表达，12例（12%）卵巢浆液性癌PARP低表达;所有病例均观察到MIB-1染色（平均44.2;范围10.8-66.5），39例（78%）p53阳性。PARP免疫反应性随着国际妇产科联合会的分期（P = 0.0075）、p53阳性（P = 0.0141）和MIB-1 LI（P = 0.0102）而增加，根据Malpica等的分级确定。（P = 0.0445），但未采用Shimizu等人（P = 0.1495）后评估的分级。在肿瘤显示高水平PARP免疫表达的患者中观察到不良结局的趋势（P = 0.0196，对数秩检验）。本研究提示PARP在卵巢浆液性癌中表达上调，与MIB-1 Us和p53表达相关，可作为卵巢浆液性癌侵袭行为的标志物，具有预后价值。
This study investigated the expression of poly(adenosine diphosphate-ribose) polymerase (PARP) in a cohort of ovarian serous carcinomas by immunohistochemistry with regard to outcome, clinicopathologic parameters, proliferation as assessed by MIB-1 labeling indices (LIs), and p53 immunoexpresion. Formalin-fixed, paraffin-embedded archival tissues of 50 ovarian serous carcinomas were immunostained with antibodies to PARP, MIB-1, and p53. In addition, 10 benign serous cystadenomas and 10 typical serous borderline ovarian tumors were included in the PARP immunostudy. Immunostaining for PARP was scored with regard to quantity and intensity of positively stained nuclei as negative, low, or strong. The MIB-1 Us were quantitated as the percentage of positively stained nuclei in 1000 nuclei. For p53, at least 10% of tumor cells had to display nuclear staining. The expression of PARP was scored negative in all serous cystadenomas and low in serous borderline ovarian tumors. Strong PARP expression was determined in 38 cases (76%), and low expression in 12 cases (12%) of ovarian serous carcinomas; MIB-1 staining was noted in all cases (mean, 44.2; range, 10.8-66.5), positivity for p53 in 39 cases (78%). The PARP immunoreactivity increased with the International Federation of Gynecology and Obstetrics stage (P = 0.0075), as well as p53 positivity (P = 0.0141) and MIB-1 LIs (P = 0.0102), with grade determined after Malpica et at. (P = 0.0445) but not with grade assessed after Shimizu et al. (P = 0.1495). A trend for poor outcome was observed in patients whose tumors displayed high levels of PARP immunoexpression (P = 0.0196, log-rank test). This study indicates that PARP expression is frequently upregulated in ovarian serous carcinomas, related with MIB-1 Us and p53 expression, and may serve as A marker of aggressive behavior with prognostic value.